title: Aripiprazole for Tourette's syndrome: a systematic review and meta-analysis.
abstract: OBJECTIVE
  To review the efficacy and safety of aripiprazole (ARI) for Tourette's syndrome (TS).
  
  
  METHODS
  This review included randomized controlled trials (RCTs) of children and adolescents (6-18 years) with TS comparing ARI monotherapy with another monotherapies in relation to clinical improvement and adverse events.
  
  
  RESULTS
  Six RCTs with a total of 528 subjects (ARI treatment group: n = 253; control group: n = 275) met the inclusion criteria. These included two RCTs (n = 255) that compared ARI monotherapy with tiapride (TIA). Tic symptoms control assessed by Yale Global Tic Severity Scale (Standard Mean Difference (SMD) = -0.38 (Confidence Interval (CI) = -1.32 to 0.56); I(2) = 90%, P = 0.42) revealed no significant differences between the two groups. Extrapyramidal symptoms were significantly different when ARI (1.5%) was compared with haloperidol (HAL) (43.5%). No significant group differences were found in the rates of nausea/vomiting, dizziness, and dry mouth between ARI and TIA (RR = 0.57 to 1.00 (95%CI = 0.14-4.20); I(2) = 0% to 69%, P = 0.35 to 1.00).
  
  
  CONCLUSIONS
  This review found that ARI has similar efficacy to TIA and HAL for TS, while extrapyramidal symptoms were significantly less with ARI than with HAL. ARI can be considered as an alternative treatment option for TS.
authors: Beijing Anding Hospital, Capital Medical University, Beijing, China.|China National Clinical Research Center for Psychiatric Disorders, China.
authors: Wei
authors: W
authors: Zheng
authors: Beijing Anding Hospital, Capital Medical University, Beijing, China.|China National Clinical Research Center for Psychiatric Disorders, China.
authors: Xian-Bin
authors: XB
authors: Li
authors: Beijing Anding Hospital, Capital Medical University, Beijing, China.|China National Clinical Research Center for Psychiatric Disorders, China.
authors: Ying-Qiang
authors: YQ
authors: Xiang
authors: Department of Psychiatry, Chinese University of Hong Kong, Hong Kong, SAR, China.
authors: Bao-Liang
authors: BL
authors: Zhong
authors: Department of Psychiatry, Chinese University of Hong Kong, Hong Kong, SAR, China.
authors: Helen F K
authors: HF
authors: Chiu
authors: The University of Notre Dame Australia/Marian Centre, Perth, Australia.|School of Psychiatry and Clinical Neurosciences, University of Western Australia, Perth, Australia.
authors: Gabor S
authors: GS
authors: Ungvari
authors: Department of Psychiatry, University of Melbourne, Melbourne, Victoria, Australia.
authors: Chee H
authors: CH
authors: Ng
authors: Kiang Wu Nursing College of Macau, Macao, SRA, China.
authors: Grace K I
authors: GK
authors: Lok
authors: Unit of Psychiatry, Faculty of Health Sciences, University of Macau, Macao, SAR, China.
authors: Yu-Tao
authors: YT
authors: Xiang
mesh_terms: D000293:Adolescent; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000068180:Aripiprazole / Q000009:adverse effects / Q000627:therapeutic use*; D001480:Basal Ganglia Diseases / Q000139:chemically induced / Q000453:epidemiology; D002648:Child; D006220:Haloperidol / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D012720:Severity of Illness Index; D005879:Tourette Syndrome / Q000188:drug therapy* / Q000503:physiopathology; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents; D000068180:Aripiprazole; D006220:Haloperidol
keywords: RCT; Tourette's syndrome; aripiprazole; children